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Abstract
Endothelial dysfunction is common in acute and chronic organ injury. Isoflurane is a widely used halogenated volatile
anesthetic during the perioperative period and protects against endothelial cell death and inflammation. In this study, we
tested whether isoflurane induces endothelial ecto-59-nucleotidase (CD73) and cytoprotective adenosine generation to
protect against endothelial cell injury. Clinically relevant concentrations of isoflurane induced CD73 activity and increased
adenosine generation in cultured human umbilical vein or mouse glomerular endothelial cells. Surprisingly, isoflurane-
mediated induction of endothelial CD73 activity occurred within 1 hr and without synthesizing new CD73. We determined
that isoflurane rapidly increased CD73 containing endothelial microparticles into the cell culture media. Indeed,
microparticles isolated from isoflurane-treated endothelial cells had significantly higher CD73 activity as well as increased
CD73 protein. In vivo, plasma from mice anesthetized with isoflurane had significantly higher endothelial cell-derived
CD144+ CD73+ microparticles and had increased microparticle CD73 activity compared to plasma from pentobarbital-
anesthetized mice. Supporting a critical role of CD73 in isoflurane-mediated endothelial protection, a selective CD73
inhibitor (APCP) prevented isoflurane-induced protection against human endothelial cell inflammation and apoptosis. In
addition, isoflurane activated endothelial cells Rho kinase evidenced by myosin phosphatase target subunit-1 and myosin
light chain phosphorylation. Furthermore, isoflurane-induced release of CD73 containing microparticles was significantly
attenuated by a selective Rho kinase inhibitor (Y27632). Taken together, we conclude that the volatile anesthetic isoflurane
causes Rho kinase-mediated release of endothelial microparticles containing preformed CD73 and increase adenosine
generation to protect against endothelial apoptosis and inflammation.
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Introduction
More than 1 trillion endothelial cells in human body cover the
entire circulatory system and play an integral role in maintaining
homeostasis of all organs [1]. Endothelial cells regulate vascular
tone, angiogenesis, coagulation and release several critically
important autocrine and paracrine compounds including sphin-
gosine 1-phosphate, adenosine, nitric oxide, and prostaglandins
[2,3]. Furthermore, endothelial cells release microparticles origi-
nating from plasma membrane and these microparticles contain
many biological active compounds including cell surface enzymes,
membrane receptors as well as lipoproteins, RNAs and micro-
RNAs [4]. Clinically, endothelial dysfunction contributes to acute
and chronic vascular and organ injury [2,3]. Indeed, endothelial
cell death occurs frequently after ischemia and reperfusion injury,
diabetes, coronary artery disease and sepsis [3,5,6].
Volatile anesthetic is administered to virtually all patients
subjected to general anesthesia making it one of the most
frequently used medications during the perioperative period [7].
Volatile anesthetics have non-anesthetic effects on the heart,
vasculature and respiratory system by regulating blood pressure,
heart rate, airway tone and systemic vascular resistance [8,9]. In
addition, volatile anesthetics have anti-necrotic and anti-inflam-
matory effects and protect against ischemia reperfusion injury of
the heart, kidney and intestine [9–11]. Furthermore, volatile
anesthetics attenuate the hyperactive systemic inflammatory
response during sepsis [12].
After inhalation, volatile anesthetics are first taken up by the
pulmonary circulatory system and all endothelial cells in the body
are rapidly exposed. We and others previously demonstrated that
volatile anesthetics protect against endothelial cell necrosis,
apoptosis and inflammation due to hypoxia, lipopolysaccharide
and cytokine exposure [13–17]. However, the detailed signaling
mechanisms of volatile anesthetic-mediated endothelial protection
remain incompletely understood. We recently demonstrated that
one of the most widely used volatile anesthetic isoflurane (2-chloro-
2-(difluoromethoxy)-1,1,1-trifluoro-ethane) induces the expression
of ecto-59-nucleotidase (CD73) in renal proximal tubular cells [18].
Isoflurane-mediated induction of CD73 activity with subsequently
increased synthesis of adenosine reduces proximal tubular
necrosis, apoptosis and inflammation after renal ischemia and
reperfusion injury. In this study, we tested whether isoflurane
stimulates endothelial CD73 activity and generates adenosine to
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protect against endothelial cell death and inflammation. To our
surprise, isoflurane did not induce new CD73 synthesis in
endothelial cells as observed in renal proximal tubular cells.
Instead, we determined that isoflurane activates endothelial cell
Rho kinase to release preformed CD73 contained within
endothelial microparticles to increase adenosine generation to
protect endothelial apoptosis and inflammation.
Methods and Materials
Ethics Statement
All animal work was approved by Columbia University
Institutional Animal Care and Use Committee.
Endothelial Cell Culture and Exposure to Isoflurane
Immortalized human umbilical vein endothelial cells
(EA.hy926, American Type Culture Collection, Manassas, VA)
cells were grown in high-glucose DMEM plus 10% FBS.
Immortalized mouse glomerular endothelial cells (GENC) were
obtained from Dr. M. Madaio (Georgia Regents University) and
grown in low glucose DMEM/Ham’s F12 medium plus 10% FBS,
2 mM l-glutamine, and 10 mM HEPES [19]. Cells were plated in
6-well plates when 80% confluent and used in the experiments
described below when confluent after 24 hr serum deprivation.
Endothelial cells were exposed to isoflurane (Abbott Laborato-
ries, Chicago, IL) as described previously [13]. In brief, endothelial
cells were placed in an air-tight, 37uC, humidified modular
incubator chamber (Billups-Rothenberg, Del Mar, CA) and
exposed to 0–2.5% (0–2 MAC) isoflurane (where 1 MAC is
defined as the percent concentration in the alveolus of an inhaled
anesthetic agent required to prevent 50% of subjects from moving
in response to a painful stimulus when used as the sole anesthetic)
mixed with 95% air+5% CO2 (carrier gas). Exposure to isoflurane
lasted between 0 to 16 hr. To inhibit CD73 or Rho kinase activity,
some endothelial cells were pretreated with 100 mM a,b-methy-
lene ADP (APCP, a selective CD73 inhibitor, Sigma, St Louis,
MO) or with 10 mM Y27632 (a selective Rho Kinase inhibitor,
Sigma, St Louis, MO) 30 min. before isoflurane treatment [20].
Microparticle Isolation and Flow Cytometry
After Columbia University Institutional Animal Care and Use
Committee approval, we anesthetized adult male C57BL/6
(Harlan, Indianapolis, IN) to 4 hr of equipotent doses of either
pentobarbital or isoflurane (1.2% or ,1 MAC) as described
previously [18]. The mice were placed on a heating pad under a
warming light to maintain body temperature ,36–38uC. After
4 hr, animals were killed and plasma isolated for microparticle
isolation.
Microparticles were isolated by differential centrifugation as
described by Amabile et al. [21]. Endothelial cell culture medium
or mouse plasma was centrifuged once at 1,0006g for 10 min to
remove the cell pellet and the resulting supernatant was
centrifuged at 20,0006g for 40 min. The resulting pellet
containing microparticles was analyzed for CD73 activity as well
as CD73 immunoblotting.
We also subjected isolated endothelial and mouse plasma
microparticles to flow cytometric analysis with a Quanta SC flow
cytometer (Beckman Coulter, Miami, FL). To determine the
relative expression of CD73, microparticles isolated from endo-
thelial cell culture media were stained with Annexin V (Beckman
Coulter, Miami, FL) and CD73 (BD Biosciences, San Jose, CA) for
5 min at room temperature. Mouse plasma microparticles were
stained with CD73 and CD144 (an endothelial cell marker, BD
Biosciences, San Jose, CA) to determine the CD73 expression in
endothelial microparticles.
Induction of Endothelial Cell Apoptosis and Inflammation
After exposure to 2.5% isoflurane or with carrier gas for 1 hr,
EA.hy9262 cells were exposed to tumor necrosis factor-alpha
(TNF-a, 20 ng/ml) plus cycloheximide (10 mg/ml) for 16 hr to
induce apoptosis or to TNF-a (20 ng/ml) for 6 hr to induce
inflammation as described previously [18]. Apoptosis was assessed
by detecting poly-(adensosine diphosphate-ribose)-polymerase
(PARP) and caspase 3 fragmentations as described [22,23].
Inflammation was assessed by measuring mRNAs encoding
markers of inflammation including TNF-a, ICAM-1 and
VCAM-1 (Table 1) with RT-PCR as described previously [18,24].
Detection of Endothelial CD73 mRNA and Protein
Expression
We measured mRNA encoding human CD73 after isoflurane
treatment as described [25] with primers listed in Table 1. In
addition, EA.hy9262 cell lysates were collected for immunoblot-
ting analyses of CD73 (Santa Cruz Biotechnologies, Santa Cruz,
CA) and b-actin (internal protein loading control, Sigma, St Louis,
MO) as described previously after isoflurane treatment [25].
HPLC to Measure Endothelial Cell Adenosine Generation
EA.hy9262 or mouse glomerular endothelial cell culture media
were collected after isoflurane treatment and assayed for adenosine
by HPLC as described [18]. Adenosine was quantified on a C18
reversed-phase column with a binary low-pressure gradient elution
system with a UV detector set to 254 nm as described [26].
Adenosine deaminase activity and adenosine uptake were inhib-
ited with 10 mM erythro-9-(2-hydroxy-3-nonly)adenine (EHNA)
and 10 mM dipyridamole, respectively.
Endothelial Cell Lysate or Microparticle CD73 Activity
Assay
CD73 activity was measured by tracking the conversion of AMP
to adenosine with or without 100 mM APCP using a modified
protocol according to Gelain et al. [27].
Rho Kinase Activity Assay and Phospho-myosin Light
Chain Immunoblotting
After 30 min treatment with 2.5% isoflurane or with carrier gas,
we measured EA.hy9262 cell Rho kinase activity with a
commercial assay that measures myosin phosphatase target
subunit-1 (MYPT-1) Threonine residue 696 phosphorylation
(Millipore, Billerica, MA). We also assessed Rho kinase activation
by detecting myosin light chain (MLC) Serine-19 phosphorylation.
EA.hy9262 cell lysates were probed with anti-phosphor-MLC 2
antibody as well as total-MLC 2 antibody (1:10,000 anti-MLC20
(:1000, Cell Signaling Technology, Danvers, MA) and subjected to
immunoblotting as described [18].
Statistical Analysis
The data were analyzed with Student’s t-test when comparing
means between 2 groups or with one way analysis of variance plus
TUKEY’s post hoc multiple comparison test to compare mean
values across multiple treatment groups. All data are expressed
throughout the text as means 6 SEM.
Isoflurane Releases Endothelial Microparticle CD73
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Results
Isoflurane Increases Adenosine Generation in Cultured
Endothelial Cells
We first determined whether isoflurane treatment increases
adenosine generation in endothelial cells. Human umbilical vein
(EA.hy9262) or mouse glomerular endothelial cells (GENC) were
treated with 0–2.5% isoflurane for 6 hr and we measured
adenosine levels in cell culture media with HPLC as described
previously [18]. We determined that isoflurane treatment signif-
icantly increased adenosine levels in human and mouse endothelial
cell culture media when compared with carrier gas-treated (room
air plus 5% CO2) cells (Figure 1A).
Isoflurane Transiently Increases CD73 Activity in Cultured
Endothelial Cells
The next set of experiments determined whether isoflurane
stimulates CD73 activity to increase adenosine generation in
cultured endothelial cells. EA.hy9262 cells had significantly
increased cell surface CD73 activity (conversion of AMP to
adenosine) 1 to 3 hr after treatment with 2.5% isoflurane
(Figure 2A). We also observed increased CD73 activity in
EA.hy9262 cells with 1.25–2.5% isoflurane treatment for 3 hr
(Figure 2B). Surprisingly, CD73 activity subsequently decreased
with longer duration of isoflurane treatment (Figure 2A). Further-
more, transient increase in CD73 activity in EA.hy9262 cells did
not require the induction of new CD73 synthesis as CD73 mRNA
(Figure 2C) and protein (Figure 2D) did not increase with
isoflurane treatment in these cells. Therefore, our studies show
that isoflurane transiently increases CD73 activity without
inducing new CD73 synthesis in cultured endothelial cells.
Table 1. Primers used to amplify cDNAs based on published GenBank sequences for human.
Primers Sequence (Sense/Antisense) Product Size (bp) Cycle Number Annealing Temp (uC)
TNF-a 59-CGGGACGTGGAGCTGGCCGAGGAG-39 355 24 68
59-CACCAGCTGGTTATCTCTCAGCTC-39
ICAM-1 59-GCAGACAGTGACCATCTACAGC-39 400 16 60
59-GCCATCCTTTAGACACTTGAGC-39
VCAM-1 59-TCTTGTTTGCCGAGCTAAATTA-39 364 22 55
59-TAAATGGTTTCTCTTGAACAA-39
CD73 59-CCA ATT CTG AGT GCA AAC AT-39 315 23 62
59-CCT CCC ACC ACG ACG TCC AC-39
GAPDH 59-ACCACAGTCCATGCCATCAC-39 450 15 65
59-CACCACCCTGTTGCTGTAGCC-39
bp, base pairs; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; ICAM-1, intercellular adhesion molecule-1; TNF-a, tumor necrosis factor-alpha; VCAM-1, vascular
cell adhesion molecule-1; CD73, Ecto-59-nucleotidase. Respective anticipated PCR product size (bp, base pairs), PCR cycle number for linear amplification, and annealing
temperatures used for each primer are also provided.
doi:10.1371/journal.pone.0099950.t001
Figure 1. Isoflurane increases adenosine generation in cultured endothelial cells. Adenosine in media from human umbilical vein
endothelial cells (EA.hy926, A) or mouse glomerular endothelial cells (GENC, B) measured with high pressure liquid chromatography. Isoflurane
treatment (0–2.5%) for 6 hr increased adenosine concentrations when compared to carrier gas-treated controls (N= 5). Data are presented as means
6 SEM. *P,0.05 vs. carrier gas-treated controls. Error bars represent 1 SEM.
doi:10.1371/journal.pone.0099950.g001
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Isoflurane Treatment Release Endothelial Cells
Microparticles Containing CD73
Since isoflurane transiently increases cell plasma membrane
CD73 activity without inducing new CD73 synthesis in cultured
endothelial cells, we tested whether isoflurane induces the release
of plasma membrane microparticles containing CD73. Indeed,
microparticles isolated from cell culture media of EA.hy9262 cells
treated with 1.25 or 2.5% isoflurane for 1 hr had significantly
increased CD73 activity compared to microparticles isolated from
carrier gas-treated cells (Figure 3A). Isoflurane (2.5%) treatment
for 1 hr also increased CD73 activity in microparticles isolated
from GENC media (Figure 3B). Finally, microparticles from
endothelial cells treated with 2.5% isoflurane had significantly
increased CD73 protein expression compared to microparticle
isolated from carrier gas-treated endothelial cells (Figure 3C and
3D). Flow cytometric analyses confirmed that endothelial cells
treated with 2.5% isoflurane for 1 hr had significantly (,50%)
higher CD73+ Annexin V+ microparticles compared to micro-
particles isolated from carrier gas-treated endothelial cells
(Figure 4).
Isoflurane Increases CD73 Containing Endothelial-derived
Microparticles in Mouse Plasma
We next determined whether isoflurane anesthesia increases
endothelial cell-derived CD73 containing microparticles in plasma
of mice anesthetized with isoflurane. Figure 5A shows that plasma
of mice anesthetized with 1.2% isoflurane for 3 hr had signifi-
cantly increased CD144 (an endothelial cell marker)+ CD73+
microparticles compared to microparticles isolated from mice
anesthetized with equi-anesthetic dose of pentobarbital. Further-
more, plasma microparticles isolated from mice anesthetized with
isoflurane had significantly higher CD73 activity when compared
to CD73 activity in plasma microparticles isolated from pento-
barbital-anesthetized mice (Figure 5B).
Isoflurane Reduces Endothelial Cell Apoptosis and
Inflammation via Induction of Endothelial Microparticle
CD73
We then tested whether CD73 is critical for isoflurane-mediated
protection against endothelial apoptosis and inflammation.
EA.hy9262 cells pretreated with carrier gas underwent apoptosis
with robust PARP and caspase-3 fragmentation (Figure 6A) after
TNF-a and cycloheximide treatment for 16 hr. In contrast,
EA.hy9262 cells pretreated with 2.5% isoflurane for 1 hr had
reduced apoptotic death indicated by decreased PARP and
caspase-3 fragmentation. Supporting a critical role of CD73
activation in isoflurane-mediated protection against endothelial
cell apoptosis, cells pretreated with a selective CD73 inhibitor
APCP (100 mM) were not protected against endothelial apoptosis
with isoflurane treatment (Figure 6A). Endothelial cells treated
with TNF-a for 6 hr showed induction of several pro-inflamma-
tory mRNAs including TNF-a, ICAM-1 and VCAM-1. Isoflurane
pretreatment reduced the upregulation of these pro-inflammatory
mRNAs. Again supporting a critical role of endothelial CD73 in
isoflurane-mediated reduction in inflammation, endothelial cells
pretreated with a selective CD73 inhibitor APCP (100 mM) were
not protected against endothelial inflammation with isoflurane
treatment (Figure 6B).
Figure 2. Isoflurane transiently increases CD73 activity without changing CD73 synthesis in cultured endothelial cells. A. Human
umbilical vein endothelial (EA.hy926) cells treated with 2.5% isoflurane showed a significant but transient induction of CD73 activity. CD73 activity
peaked at 3 hr and then decreased to near baseline at 6–16 hr after isoflurane treatment (N= 6–8). B. Isoflurane treatment for 3 hr caused dose-
dependent increase in CD73 activity in EA.hy926 cells compared to carrier gas-treated cells (N = 4–5). Data are presented as means 6 SEM. *P,0.05
vs. CD73 activity measured at baseline (A) or in cells treated with 0% isoflurane (B). C and D. Representative images for CD73 mRNA (RT-PCR) and
protein (immunoblotting) expression in EA.hy926 cells. EA.hy926 cells were treated with carrier gas or with 2.5% isoflurane for 6 hr (C) or for 16 hr (D).
Isoflurane treatment did not increase CD73 mRNA or protein expression in EA.hy926 cells. Representative of 3–4 experiments.
doi:10.1371/journal.pone.0099950.g002
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Isoflurane-mediated Activation of Rho Kinase Mediates
the Release of Endothelial Microparticles Containing
CD73
Since previous studies showed that Rho kinase activation
increases endothelial microparticle generation [28–30], we tested
the hypothesis that isoflurane activates endothelial Rho kinase to
release endothelial microparticles containing CD73. Figure 7A
shows a significant increase in Rho kinase activity (detected by
MYPT-1 phosphorylation) in EA.hy9262 cells treated with 2.5%
isoflurane for 30 min. compared to carrier gas. Furthermore,
Figure 7B shows increased p-MLC immunoreactivity in
EA.hy9262 cells treated with 2.5% isoflurane for 30 min. Total
MLC immunoreactivity did not change with isoflurane treatment.
In addition, we were able to block isoflurane-mediated MLC
phosphorylation with a selective inhibitor of Rho kinase (Y27632,
data not shown). Finally, Figure 8 shows that a selective Rho
kinase inhibitor Y27632 prevented isoflurane-mediated increases
in microparticle CD73 activity in EA.hy9262 cells supporting a
critical role for Rho kinase in isoflurane-mediated release of CD73
containing endothelial microparticles.
Discussion
Overactive inflammatory response is a detrimental complication
of surgery and perioperative surgical infections. Anti-inflammatory
and cytoprotective effects of volatile inhalational anesthetics are
well recognized [31,32]. However, the mechanisms mediating the
protective effects of volatile anesthetics have not been fully
elucidated. Our findings suggest that volatile anesthetics, at least
in part, attenuate endothelial inflammation and apoptosis by
releasing CD73 containing endothelial microparticles. We found
that clinically relevant concentrations of isoflurane (1.25–2.5%)
increased adenosine generation and rapidly increased endothelial
CD73 activity in cultured human umbilical vein endothelial and
mouse glomerular endothelial cells. We were surprised to discover
that isoflurane-mediated induction of CD73 activity was transient
and occurred without any changes in CD73 expression. We
determined that isoflurane-mediated induction of CD73 activity
was due to the release of preformed CD73 contained in
endothelial plasma membrane microparticles. CD73 activity was
critical for isoflurane-mediated protection against endothelial
apoptosis and inflammation. Finally, the mechanisms of isoflur-
ane-mediated release of CD73 containing microparticles are
mediated by activation of endothelial Rho kinase.
In addition to its analgesic and anesthetic properties, volatile
anesthetics have non-anesthetic effects in virtually every cell type.
Importantly, volatile anesthetics protect against cell death and
inflammation in several key organs including the heart, brain,
kidney and intestine. For example, several clinically utilized
volatile anesthetics including isoflurane precondition the heart
Figure 3. Isoflurane releases CD73 containing microparticles in cultured endothelial cells. A. Human umbilical vein endothelial (EA.hy926)
cells were treated with 0–2.5% isoflurane for 1 hr and endothelial cell culture media microparticles (MP) were isolated and assayed for CD73 activity.
Isoflurane caused a significant increase in human endothelial cell microparticle CD73 activity (N = 5–8). B. Microparticles isolated from mouse
glomerular endothelial cells (GENC) treated with 2.5% isoflurane for 1 hr also had higher CD73 activity compared to carrier gas-treated cells (N = 4–6).
C and D. Representative CD73 immunoblotting images (C) and band intensity quantifications (D) from microparticles isolated from EA.hy926 cells.
Beta-actin protein expression was also quantified to normalize lane loading. Isoflurane treatment (2.5% for 1 hr) significantly increased CD73 protein
expression in EA.hy926 cell microparticles compared to carrier gas-treated cells. *P,0.05 vs. carrier gas group. Error bars represent 1 SEM.
doi:10.1371/journal.pone.0099950.g003
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against ischemia and reperfusion injury [11]. We have previously
demonstrated that volatile anesthetics including isoflurane display
anti-necrotic and anti-inflammatory effects in renal proximal
tubule cells in vivo and in vitro [5,12,13]. Harnessing these non-
anesthetic properties of volatile anesthetics may have important
clinical implications for critically ill patients anesthetized in the
OR and sedated in the ICU.
Previous studies have shown that isoflurane anesthesia in mice
and rats attenuates lipopolysaccharide induced endothelial inflam-
mation [16,17]. Furthermore, isoflurane inhalation after LPS
injection in rats in vivo attenuates systemic cytokine (IL-1b and IL-
6) upregulation and well as lung injury [33,34]. We previously
showed that volatile anesthetic isoflurane protect against human
endothelial apoptosis and inflammation [13,35]. Consistent with
our findings, others have also shown that isoflurane treatment
attenuated lipopolysaccharide or TNF-a induced endothelial cell
inflammation and death in vitro [14,36]. Although the robust anti-
inflammatory and protective effects of isoflurane have been
demonstrated in vivo and in vitro, the detained cytoprotective
mechanisms remained elusive.
We recently showed that isoflurane protected against renal
tubular necrosis, apoptosis and inflammation by direct induction
of CD73 enzyme and activity leading to enhanced adenosine
generation [18]. CD73 is a well-known anti-inflammatory and
anti-ischemic enzyme. Mice deficient in CD73 have increased
tissue and vascular inflammation and have a higher mortality rate
after ischemia and reperfusion injury and sepsis [37,38] [39].
Moreover, enhanced CD73 activity protects against intestinal,
cardiac and renal ischemia reperfusion injury [37,38,40]. Cell
surface CD73 catalyzes the hydrolysis of AMP to adenosine and is
a critical step in extracellular adenosine generation [41].
Extracellular adenosine regulates diverse and important physio-
logical effects including cardiac inotropy and chronotropy,
vascular tone and kidney glomerular filtration rate. Furthermore,
adenosine protects against tissue injury and inflammation after
ischemia and reperfusion or sepsis. Adenosine acts via activation of
4 G-protein coupled purinergic receptors [A1, A2a, A2b and A3
adenosine receptors] [41,42]. In particular, activation of A1, A2a or
A2bARs protects against ischemia reperfusion injury in the kidney,
heart, liver and brain [43,44]. Unlike findings in renal proximal
tubular cells where CD73 synthesis was increased after isoflurane
treatment, isoflurane increases adenosine generation in endothelial
cells by releasing preformed CD73 contained in endothelial
plasma membrane microparticles without synthesizing new CD73
Figure 4. Flow cytometric analyses of endothelial cell culture media microparticles. A. Representative flow cytometric analyses of
microparticles isolated from EA.hy926 endothelial cell culture media. EA.hy926 cells were treated with 2.5% isoflurane or with carrier gas for 1 hr and
isolated microparticles were incubated with CD73 antibody and Annexin V. B. EA.hy926 cells treated with 2.5% isoflurane for 1 hr had significantly
higher CD73+ Annexin V+ microparticles compared to microparticles isolated from carrier gas-treated endothelial cells (N = 5). *P,0.05 vs. carrier gas
group. Error bars represent 1 SEM.
doi:10.1371/journal.pone.0099950.g004
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enzyme [18]. The exact subtype(s) of adenosine receptor(s)
involved in endothelial protection by isoflurane-mediated adeno-
sine generation remains to be elucidated.
In this study, we demonstrate that isoflurane rapidly released
endothelial microparticles containing preformed CD73 in cultured
endothelial cells as well as in plasma of mice. Indeed, CD73 was
directly responsible for isoflurane-mediated endothelial cell
protection. Plasma membrane microparticles are phospholipid
microvesicles of submicron (0.1 to 1.0 mm) fragments that
originate from plasma membrane blebbing and are subsequently
shed [4,45]. Microparticles play an important role in the transfer
of materials between cells. Furthermore, they are critical in
transferring signaling information to cells close by or far away.
Plasma microparticles are elevated in several pathological
conditions including vascular thrombosis, hyperlipidemia, diabe-
tes, chronic renal dysfunction and cancer [4,28,46]. Here we show
that endothelial microparticles could also have a cytoprotective
and beneficial role. We propose that isoflurane treatment
propagates the systemic release of endothelial microparticles
containing active CD73 that function as cytoprotective messengers
by generating adenosine. Isoflurane-mediated endothelial micro-
particle generation may prevent damage and favor vascular repair
by preventing endothelial apoptosis and inflammation. Further-
more, microparticle-mediated delivery of CD73 allows adenosine
formation in different cell types (e.g., epithelial cell). Finally,
microparticle generation allows remote delivery of CD73 away
Figure 5. Isoflurane increases CD73 containing endothelial cell-
derived microparticles in mouse plasma. Mouse plasma micro-
particles (MP) were isolated after 1.2% isoflurane or equi-anesthetic
dose of pentobarbital anesthesia for 3 hr. A. Mice anesthetized with
isoflurane had significantly increased CD144 (endothelial cell marker)+
CD73+ plasma microparticles compared to mice anesthetized with
pentobarbital (N= 4). B. Plasma microparticles isolated from mice
anesthetized with isoflurane had significantly higher CD73 activity
when compared to CD73 activity in microparticles isolated from
pentobarbital-anesthetized mice (N= 5). *P,0.05 vs. carrier gas group.
Error bars represent 1 SEM.
doi:10.1371/journal.pone.0099950.g005
Figure 6. Isoflurane reduces endothelial cell apoptosis and
inflammation via CD73. A. Representative immunoblot of poly(-
adenosine diphosphate-ribose) polymerase (PARP) and caspase-3
fragmentation (N= 4) as indices of EA.hy926 endothelial cell apoptosis
induced by TNF-a (20 ng/ml) and cycloheximide (CHX; 10 mg/ml)
treatment for 16 hr. EA.hy926 cells treated with TNF-a and cyclohex-
imide for 16 hr had robust PARP and caspase-3 fragmentation. In
contrast, EA.hy926 cells treated with 2.5% isoflurane for 1 hr before the
induction of apoptosis isoflurane showed reduced apoptotic death
indicated by decreased PARP and caspase-3 fragmentation. Supporting
a critical role of CD73 in isoflurane-mediated protection against
EA.hy926 cell apoptosis, cells pretreated with a selective CD73 inhibitor
APCP (100 mM) were not protected against endothelial apoptosis with
isoflurane pretreatment. B. Representative gel images of pro-inflamma-
tory mRNA expression (VCAM-1, ICAM-2 and TNF-a) in EA.hy926
endothelial cells treated with TNF-a (20 ng/ml) for 6 hr. EA.hy926 cells
treated with TNF-a had increased mRNA encoding markers of
inflammation. In contrast, EA.hy926 cells treated with 2.5% isoflurane
for 1 hr before TNF-a treatment had reduced inflammatory mRNA
expression. Again, supporting a critical role of CD73 in isoflurane-
mediated protection against EA.hy926 cell inflammation, cells pretreat-
ed with a selective CD73 inhibitor APCP were not protected against
endothelial inflammation with isoflurane pretreatment.
doi:10.1371/journal.pone.0099950.g006
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from the originating endothelial cell. Our findings imply that
isoflurane-mediated generation of CD73 containing microparticles
in one organ (e.g., lung) may travel to distant locations (e.g.,
kidney, liver) to produce multi-organ anti-inflammatory effects
(Figure 9).
We also demonstrate an important role for Rho kinase
activation in isoflurane-mediated CD73 containing endothelial
microparticle release. We show in this study that isoflurane-
mediated endothelial microparticle release and induction of CD73
activity were significantly attenuated by a selective Rho kinase
inhibitor. In many cell types including endothelial cells, Rho
kinase regulates cytoskeleton architecture, migration and growth
[47,48]. Previous studies suggest that volatile anesthetics including
isoflurane activate Rho kinase and promote Rho A function. In
primary neuronal cultures as well as rat glioma C6 cell line, Rho A
was activated after exposure to ,1 MAC isoflurane [49,50].
Evidence for Rho kinase-mediated endothelial microparticle
formation and release also provided by Burger et al [28]. They
showed that angiotensin II-mediated microparticle formation is
mediated by Rho kinase pathways targeted to lipid rafts. In
addition, thrombin induces endothelial microparticle generation
via Rho kinase activation [29]. Finally, endothelial microparticles
released with TNF-a treatment in human coronary artery
endothelial cells are suppressed by a specific Rho kinase inhibitor
(Y-27632) [30].
In summary, we demonstrate that a commonly utilized volatile
anesthetic isoflurane rapidly increases endothelial cell adenosine
generation via releasing microparticles containing preformed
CD73. Release of CD73 and subsequent adenosine generation
may result in cellular protection in neighboring and remote
endothelial and epithelial cells via activation of adenosine
receptors. Our current findings in endothelial cells differ
considerably from findings in renal tubular epithelial cells as
increased adenosine generation occurred without the induction of
new CD73 synthesis. Taken together, our current study provides
additional mechanistic insight into the mechanism of isoflurane-
mediated endothelial cell protection.
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target protein-1 phosphorylation after treatment with 2.5% isoflurane
or with carrier gas for 30 min. Isoflurane significantly increased Rho
kinase activity in EA.hy9262 cells compared to carrier gas-treated cells
(N = 5). *P,0.05 vs. carrier gas group. Error bars represent 1 SEM. B.
EA.hy9262 endothelial Rho kinase activity was also assessed by
detecting myosin light chain (MLC) phosphorylation in EA.hy9262 cells
with immunoblotting. MLC phosphorylation increased in EA.hy9262
cells treated with 2.5% isoflurane for 30 min compared to carrier gas-
treated cells. Total MLC immunoreactivity did not change with
isoflurane treatment. Representative of 2 experiments performed in
triplicate.
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Figure 8. Isoflurane-mediated activation of Rho kinase medi-
ates the release of CD73 containing endothelial microparticles.
Human endothelial (EA.hy9262) cells were treated with 2.5% isoflurane
or with carrier gas for 1 hr. Some cells were pretreated with a selective
Rho kinase inhibitor Y27632 for 30 min. before isoflurane or carrier gas
treatment. Y27632 prevented the isoflurane-mediated increase in
microparticle CD73 activity in EA.hy9262 cells (N = 4). *P,0.05 vs.
carrier gas group treated with vehicle. #P,0.05 vs. isoflurane group
treated with vehicle. Error bars represent 1 SEM.
doi:10.1371/journal.pone.0099950.g008
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